The effect of subunit or modified live bovine herpesvirus-1 vaccines on the efficacy of a recombinant Pasteurella haemolytica vaccine for the prevention of respiratory disease in feedlot calves

The efficacy of a Pasteurella haemolytica vaccine (PhV) administered once to calves within 24 hours of arrival at a feedlot was tested for the ability to prevent morbidity and mortality from all bovine respiratory disease (BRD) and specifically from fibrinous pneumonia mortality. The PhV consisted of two immunizing ingredients: outer membrane proteins extracted from P. haemolytica, plus genetically attenuated leukotoxin produced by recombinant DNA technology. This double blind study was conducted at a large Saskatchewan feedlot using 2,324 high-risk calves purchased at auction markets and kept under typical commercial feedlot conditions. The trial design included four vaccine test groups: 1) PhV and a bovine herpesvirus type-1 (BHV-1) subunit vaccine comprised only of the virus glycoprotein IV (gIV); 2) PhV and a commercial modified live vaccine (MLV) containing BHV-1 and parainfluenza-3 viruses; 3) gIV alone; and 4) MLV alone. Calves were assigned to vaccine groups in a random systematic manner, individually identified, and monitored for 90 days after vaccination. The vaccines were given once, on arrival, to reflect common feedlot practice, although vaccination prior to expected risk would be more appropriate.

The PhV in combination with gIV reduced BRD morbidity by 20% (p < 0.05) compared to gIV alone and 24% (p < 0.05) compared to MLV alone, and reduced BRD mortality by 88% (p < 0.05) and fibrinous pneumonia mortality by 100% (p < 0.05) when compared to either gIV or MLV alone. Vaccination with PhV in combination with MLV significantly reduced the efficacy of the PhV in preventing BRD morbidity, BRD mortality, and fibrinous pneumonia mortality and also reduced the antibody response to P. haemolytica leukotoxin. These results suggest that the MLV interfered with the protective capacity of the PhV.

     

Comparison of two formulations of oxytetracycline given prophylactically to reduce the incidence of bovine respiratory disease in feedlot calves

A trial involving 1,803 feedlot calves was conducted under commercial feedlot conditions in western Canada to compare the relative effectiveness of a new oxytetracycline formulation, administered either intramuscularly (BMI) or subcutaneously (BMS), to a currently available oxytetracycline formulation, administered intramuscularly (LAB), for the prevention of bovine respiratory disease (BRD) in feedlot calves. All experimental treatments were administered upon arrival at the feedlot and again on the third day after arrival.

Over the entire feeding period, there were no significant differences (p≥0.05) in the BRD treatment rates or the BRD relapse rates between either the BMI or BMS groups compared to the LAB group. Similarly, there were no significant differences (p≥0.05) in the BRD treatment rates in the BMI or BMS groups from days 8-14, days 15-90, or days 1-90 of the feeding period compared to the LAB group. However, during the first seven days of the feeding period the BRD treatment rate in the BMI group was 1.55 times (p<0.05) higher than in the LAB group. From days 1-90 and day 1 to the end of the feeding period, the overall mortality rates, BRD mortality rates, and BRD case fatality rates were two to six times lower in the BMS and BMI groups as compared to the LAB group; however, these differences were not statistically significant (p≥0.05).

These data indicate that both the intramuscular and subcutaneous administration of a new oxytetracycline formulation are comparable to the intramuscular administration of a currently available oxytetracycline formulation when given to calves upon arrival at the feedlot.

     

A field trial to evaluate the efficacy of a commercial Pasteurella haemolytica bacterial extract in preventing bovine respiratory disease

A double blind, random, controlled field trial was conducted to ascertain the efficacy of a Pasteurella haemolytica bacterial extract (Presponse, Langford Inc., Guelph, Ontario) in the prevention of bovine respiratory disease and/or its effects. Calves from 13 ranches (n = 1140 calves) were assigned to one of four groups, namely: vaccinated at the ranch three weeks prior to shipping to the feedlot; vaccinated only on arrival at the feedlot; vaccinated at both locations; or not vaccinated at either location. Four replicates of auction calves (n = 731) were also assigned to either receive or not receive the vaccine on arrival at the feedlot.

The vaccine did not effect a change in morbidity rates or weight gain. Total mortality rates were increased significantly, and mortality rates from respiratory disease tended to be increased in ranch calves that were vaccinated with Presponse at the ranch. In auction calves, the relapse rates were significantly lower in vaccinated calves. There was a tendency towards a reduction of respiratory disease-related mortality, however there appeared to be no sparing against death from fibrinous pneumonia in auction calves.

     

Meta-analysis of field trials of antimicrobial mass medication for prophylaxis of bovine respiratory disease in feedlot cattle

One hundred and seven field trials of prophylactic mass medication for bovine respiratory disease (BRD) in feedlot cattle were reviewed. Meta-analysis is the formal quantitative statistical review process that was used to synthesize the data from randomized field trials and draw conclusions concerning the efficacy of prophylactic mass medication in feedlot calves.

The results of the meta-analysis indicated that prophylactic parenteral mass medication of calves with long-acting oxytetracycline or tilmicosin on arrival at the feedlot would reduce BRD morbidity rates (p < 0.001). There were, however, unreliable data on the effects of mass medication on mortality rates and performance, insufficient data on the most effective treatment regimes, and no valid data on the efficacy of feed and water medication for prophylaxis of BRD.

This review highlights the gaps in our knowledge and points out the need for additional well-designed randomized controlled field trials of adequate size to assess the efficacy and socioeconomic impact of prophylactic mass medication for BRD in feedlot cattle.

     

Antimicrobial resistance in bovine respiratory disease: Auction market- and ranch-raised calves

This study compared changes in prevalence and antimicrobial susceptibility of Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni in feedlot calves derived from the auction market (AUCT; n = 299) and from a single-ranch source (RANCH; n = 300). In the AUCT calves, the prevalence of Mannheimia haemolytica decreased, whereas Histophilus somni increased over the feeding period. The AUCT calves showed an increase in isolates not susceptible to tulathromycin for all bovine respiratory disease (BRD) pathogens, an increase in Pasteurella multocida and Histophilus somni isolates not susceptible to oxytetracycline, and an increase in Pasteurella multocida isolates not susceptible to florfenicol. In the RANCH calves, the prevalence of all 3 BRD pathogens was high at feedlot entry and decreased significantly during the study period. In RANCH calves, there was a significant increase in Pasteurella multocida isolates not susceptible to oxytetracycline, tulathromycin, and florfenicol. Surprisingly, there was a significant decrease in Mannheimia haemolytica isolates that were not susceptible to oxytetracycline, tilmicosin, and tulathromycin.     

Effect of intranasal vaccination against bovine enteric coronavirus on the occurrence of respiratory tract disease in a commercial backgrounding feedlot

OBJECTIVE: To measure antibody titers against bovine coronavirus (BCV), determine frequency of BCV in nasal swab specimens, and compare calves treated for bovine respiratory tract disease (BRD) between those given an intranasally administered vaccine and control calves. DESIGN: Randomized clinical trial. ANIMALS: 414 heifer calves. PROCEDURE: Intranasal BCV antigen concentration and antibody titer against BCV were measured on entry to a feedlot. Calves were randomly assigned to receive 3.0 mL of a modified-live virus vaccine against bovine enteric coronavirus and rotavirus or 3.0 mL of saline (0.9% NaCl) solution. Calves were confined to 1 of 2 pens, depending on vaccination status, for a minimum of 17 days of observation (range, 17 to 99). Selection of calves for treatment of BRD and scoring for severity of disease were done by veterinarians unaware of treatment status. RESULTS: Intranasal BCV (125/407 [31%]) and serum antibody titers > or = 20 against BCV (246/396 [62%]) were identified in calves entering the feedlot. Vaccination was associated with significant decrease in risk of treatment for BRD; intranasal BCV on entry to the feedlot was associated with increased risk of treatment. Univariate analysis revealed that control calves with intranasal BRD on entry to the feedlot and those with antibody titer < 20 were significantly more likely to be treated for BRD. CONCLUSIONS AND CLINICAL RELEVANCE: These data provide further evidence of an association between BCV and respiratory tract disease in feedlot calves. An intranasally administered vaccine appeared to reduce risk of treatment for BRD.     

The association of titers to Haemophilus somnus, and other putative pathogens, with the occurrence of bovine respiratory disease and weight gain in feedlot calves.

Serum samples were obtained from 602 calves (from 19 groups in four feedlots: three in Ontario, and one in Alberta) upon arrival at the feedlot and 28 d later. Of these calves, 202 developed bovine respiratory disease (BRD) and 400 did not develop BRD. Based on high antibody titers noted upon arrival, we infer that most calves were exposed to Haemophilus somnus prior to arrival at the feedlot. Within a group, calves with high titers on arrival had a reduced risk of developing BRD later. Most calves did not experience titer increases after arrival; however, calves that had stable or increasing titers had a relatively low risk of contracting BRD. The calves at greatest risk of BRD were those with titers on arrival of less than 6.8 units and subsequent titer decreases of more than 1 unit. The effects of both the titer on arrival and the titer change after arrival were stable when the serologic effects of a number of viruses and Mycoplasma agents were considered. Neither antibody titer on arrival nor titer change was related to weight gain differences among calves. Calves with BRD or calves with lower weight on arrival had decreased weight gains in the first 28-day feeding period. The high titers on arrival may have protected most calves against further infection with H. somnus. However, since the calves that developed BRD had large titer increases to a number of viruses and to Pasteurella haemolytica, while having decreased antibody titers to H. somnus, we infer that the existing antibodies were "used up" in combatting the agents, including H. somnus, which may have "caused" the BRD. Calves which were able to increase their antibody levels to H. somnus tended to have a reduced risk of BRD.     

Antimicrobial Use in Feedlot Calves: Its Association with Culture Rates and Antimicrobial Susceptibility

Data were collected on anti-microbial usage and health problems, in beef feedlot calves. Although the association between them was not significant, many feedlot owners did not use recommended dosages or duration of treatment and this may have led to a reduced recovery rate.

Injectable tetracyclines were the most frequent antimicrobial for primary treatment of sick calves; whereas chloramphenicol was selected most frequently when the primary treatment appeared to be ineffective. Treatment with anti-microbials reduced the likelihood of isolating both Pasteurella multocida and Haemophilus somnus. Chloramphenicol therapy reduced the likelihood of isolating Pasteurella haemolytica.

Therapy with a particular antimicrobial, in the week prior to death, increased the level of resistance in P. haemolytica to that antimicrobial. Treatment with other antimicrobials also increased the level of resistance to that antimicrobial; although to a lesser degree. The lowest levels of resistance were observed in Pasteurella isolated from nontreated cattle. After adjustment for antimicrobial exposure, resistance to penicillin, tetracyclines and chloramphenicol occurred together more frequently than expected by chance alone.

     

Epidemiological features of calf mortality due to hemophilosis in a large feedlot

Hemophilosis was the most significant cause of mortality in fall-placed calves in a large feedlot in Saskatchewan, despite routine single immunization of calves with a commercial Haemophilus somnus bacterin on arrival. Common manifestations of fatal H. somnus infection were myocarditis and pleuritis; occasionally, thrombotic meningoencephalomyelitis (TME), peracute septicemia, and pneumonia were observed. Circumstantial evidence suggested that H. somnus may be a pathogen in polyarthritis. Death from pneumonia mainly occurred during the first five weeks in the feedlot. Death from myocarditis, pleuritis, TME, and septicemia, and euthanasia because of polyarthritis, occurred mainly after the third week in the feedlot.

The median fatal disease onset (FDO) for pneumonia was day 12; for septicemia, day 17; for polyarthritis, day 18; for myocarditis and pleuritis, day 22; and for TME, day 29. Calves that died from myocarditis frequently were found dead in their “home” pen; however, 88% of these animals had been treated previously. Fifty-seven percent of the calves that died from pleuritis were never treated, and those that died from TME or septicemia were either never treated or died shortly after initial treatment.

     

The association of titers to bovine coronavirus with treatment for bovine respiratory disease and weight gain in feedlot calves.

The association between bovine respiratory disease (BRD) and antibody titers to bovine coronavirus (BCV) was studied in 604 calves (19 different groups in 4 different feedlots from 2 provinces). Almost all calves had antibody titers on arrival in the Alberta feedlot and 82% of the calves had an antibody titer on arrival at the Ontario feedlots; titers in calves in Alberta were almost twice as high as those in calves in Ontario. The incidence of infection, in the first mo after arrival as judged by seroconversion, ranged from 61% to 100%; titer increases were much greater in calves in Ontario feedlots. Titer variables were not significantly related to BRD, except on a within-group basis (group was a confounding variable for BCV-BRD associations). Given control of group effects, calves with an antibody titer on arrival appeared to be protected against BRD for the first 28 d in the feedlot, and the association was reasonably linear over the range of titers. Each titer unit on arrival decreased the risk of BRD by about 0.8x (odds ratio). Titer change was not strongly related to the risk of BRD and the relationship was not linear over the range of titer changes. Titer change was strongly and negatively correlated with titer on arrival, and titer change was not significantly related to BRD in the presence of arrival titers. Arrival titer retained its relationship with BRD in the presence of titer data for other putative pathogens. Each higher unit of titer to BCV on arrival increased the 28-day weight gain (controlling for group, initial weight and the occurrence of BRD) by slightly more than 1 kg. Titer change was associated with decreased weight gain, when initial titer was not in the model. The lack of a linear or multivariable association between BCV titer change and BRD, and weight gain, may indicate that BCV is not a major pathogen; or, its lack of significance may merely be due to its strong correlation with arrival titer. Given the associations found in this study, particularly the interprovincial differences in arrival titers, more and different approaches to studying the possible effects of BCV on BRD are in order.     

A comparison of florfenicol and tilmicosin for the treatment of undifferentiated fever in feedlot calves in western Canada

A field trial was performed under commercial feedlot conditions in western Canada to compare the efficacy of florfenicol and tilmicosin for the treatment of undifferentiated fever (UF) in calves that received metaphylactic tilmicosin upon arrival at the feedlot. One thousand and eighty recently weaned, auction market derived, crossbred beef calves suffering from UF were allocated to one of 2 experimental groups as follows: florfenicol, which was intramuscular (i.m.) florfenicol administered at the rate of 20 mg/kg body weight (BW) at the time of allocation (Day 0) and again 48 h later, or tilmicosin, which was subcutaneous (s.c.) tilmicosin administered once at the rate of 10 mg/kg BW on day 0. Five hundred and forty-four animals were allocated to the florfenicol group and 536 animals were allocated to the tilmicosin group. The chronicity, wastage, overall mortality, and bovine respiratory disease (BRD) mortality rates were significantly (P < 0.05) lower in the florfenicol group than in the tilmicosin group. There were no significant (P > or = 0.05) differences in first UF relapse, second UF relapse, hemophilosis mortality, or miscellaneous mortality rates between the florfenicol and tilmicosin groups. Average daily gain (ADG) from arrival at the feedlot to the time of implanting and ADG from allocation to the time of implanting were significantly (P < 0.05) lower in the florfenicol group as compared with the tilmicosin group. There were no significant (P > or = 0.05) differences in arrival weight, allocation weight, implanting weight, or ADG from arrival to allocation between the experimental groups. In the economic analysis, there was an advantage of $18.83 CDN per animal in the florfenicol group. The results of this study indicate that florfenicol is superior to tilmicosin for the treatment of UF because of lower chronicity, wastage, overall mortality, and BRD mortality rates. However, interpretation of these observations must take into consideration the fact that these calves received meta-phylactic tilmicosin upon arrival at the feedlot, which is a standard, cost-effective, management procedure utilized by feedlots in western Canada.     

Five field trials on the efficacy of a bovine respiratory syncytial virus vaccine

Five field trials evaluated whether immunization of beef cattle prior to weaning, at weaning, or immediately upon arrival at the feedlot with a commercial bovine respiratory syncytial virus (BRSV) vaccine would reduce subsequent treatment for respiratory disease.

Bovine respiratory syncytial virus vaccination was associated with a significant (p<0.05) reduction in treatment rate in one of three groups of calves immunized prior to weaning (−12%) and in calves immunized upon arrival at the feedlot (−4%).

There was no significant (p>0.05) effect of the BRSV vaccine on treatment rate in calves immunized at weaning, in calves immunized upon arrival at the Saskatoon bull test station, or in yearlings immunized upon arrival at the feedlot.

Although the trend in these field trials was to a sparing effect of the BRSV vaccine, the small reduction in treatment rate may not justify the cost of the vaccination program.

     

Haemophilus somnus Infections II. A Canadian Field Trial of a Commercial Bacterin: Clinical and Serological Results

To evaluate the efficacy of a Haemophilus somnus bacterin a total of 1114 beef calves or yearling bulls were used in the province of Saskatchewan. The six herds were included in a vaccination trial in which the vaccine was administered subcutaneously in one or two doses. The prevalence of H. somnus in nasal swabs of these animals at the time of the initial vaccination was 0.35% Postvaccination information on morbidity and mortality for a four month period was requested from the five ranches where there were nonvaccinated control calves. Postvaccination outbreaks of infectious thromboembolic meningoencephalitis occurred in two of these herds and, although the numbers were limited, there was a trend to reduced morbidity and mortality in the vaccinated animals compared to controls. Seroconversion rates, as determined by the complement fixation test, in the six herds were 28.3% for control calves, 57% for animals vaccinated once and 80.3% for animals vaccinated twice. On the basis of these results the bacterin was considered to be sufficiently efficacious to warrant its further evaluation under field conditions.     

Evaluation of health status of calves and the impact on feedlot performance: assessment of a retained ownership program for postweaning calves

The objective of this study was to evaluate animal health status at entry to a feedlot against feedlot performance and carcass value. There were 24 herds represented by 417 calves in a retained ownership program. The health status at entry was represented by the levels of serum antibody to infectious bovine rhinotracheitis virus (IBRV), bovine viral diarrhea viruses 1 and 2 (BVDV1a, BVDV2), parainfluenza 3 virus (PI3V), bovine respiratory syncytial virus (BRSV), Mannheimia haemolytica, and Pasteurella multocida, as well as by the presence of virus in nasal swabs and blood leukocytes and the presence of bacteria in nasal swabs. The presence or absence of viruses or bacteria at entry did not predict subsequent illness. However, there were predictors of illness severity (number of treatments) and performance parameters of feedlot performance. Herds with a low morbidity rate had higher levels of BVDV1a antibodies than herds with a high morbidity rate. On both an individual-animal and a herd-average basis, calves with low levels of antibody to BVDV1a and BVDV2 had increased total treatment costs. Also, for individual animals and the herd as a whole, low levels of antibody to P. multocida, BVDV1a, and BVDV2 were related to decreased net value to owner (carcass value minus total feedlot cost). Calves treated twice or more had lower levels of antibody to BVDV1a than those treated once or not at all. Differences in herd morbidity rate and treatment costs were more related to appropriate timing of vaccine (last dose at or near delivery of calf) or lack of a 2nd dose of killed vaccine. This was best illustrated by the levels of antibody to BVDV1a. The results of this study were used to formulate recommendations for the subsequent year.     

A comparison of 2 vaccination programs in feedlot calves at ultra-high risk of developing undifferentiated fever/bovine respiratory disease

The aim of this study was to compare 2 vaccination programs in feedlot calves at ultra-high risk of developing undifferentiated fever (UF)/bovine respiratory disease (BRD). At feedlot arrival, 3882 calves were enrolled in the study and randomly allocated to 2 groups, which were housed by group in 12 pens. At the time of allocation, 1 group (MLV3-BT2) received a multivalent, modified-live viral vaccine containing infectious bovine rhinotracheitis virus (IBRV) and types I and II bovine viral diarrhea virus (BVDV), as well as a Mannheimia haemolytica (MH) and Pasteurella multocida bacterin-toxoid. The other group (MLV4-BT1) received a vaccine containing IIBRV, type I BVDV, bovine respiratory syncytial virus, and parainfluenza-3 virus, as well as a MH bacterin-toxoid. At an average of 69 days post arrival, the groups received their respective viral vaccines. The initial UF treatment, overall chronicity, overall wastage, overall mortality, and BRD mortality rates were significantly (P < 0.05) lower in the MLV3-BT2 group than in the MLV4-BT1 group. Average daily gain and the proportions of yield grade Canada 3 and quality grade E carcasses were significantly (P < 0.05) higher in the MLV3-BT2 group than in the MLV4-BT1 group. No significant (P > or = 0.05) difference in the dry matter intake to gain ratio was detected between the 2 groups. In economic terms, there was a net advantage of $20.86 CDN/animal in the MLV3-BT2 group. This study demonstrates that it is more cost effective to use an MLV3-BT2 vaccination program than a MLV4-BT1 vaccination program in feedlot calves at ultra-high risk of developing UF/BRD.     

A field trial of preshipment vaccination of calves

A field trial to investigate the efficacy of vitamins ADE, a Haemophilus somnus bacterin, a pasteurella bacterin, and two intranasal infectious bovine rhinotracheitis-parainfluenza type 3 vaccines administered to beef calves at least three weeks prior to weaning and shipment was conducted.

Over 1000 calves were vaccinated, but of the 692 calves shipped from the ranch of origin, only 276 calves were located in Ontario, or Quebec, feedlots. The average treatment rate was 30%. Neither vitamins ADE, H. somnus bacterin, pasteurella bacterin or the porcine tissue culture infectious bovine rhinotracheitis-parainfluenza type 3 vaccine had a significant effect on treatment rates for respiratory disease. Calves vaccinated with the temperature sensitive infectious bovine rhinotracheitis-parainfluenza type 3 vaccine had a significantly (p < 0.05) lower treatment rate than the nonvaccinated, and the porcine tissue culture infectious bovine rhinotracheitis-parainfluenza type 3 vaccinated, calves. Calves vaccinated with the temperature sensitive infectious bovine rhinotracheitis-parainfluenza type 3 vaccine did not have a significantly reduced treatment rate in comparison to nonvaccinated calves from the same source.

     

Associations between the distance traveled from sale barns to commercial feedlots in the United States and overall performance, risk of respiratory disease, and cumulative mortality in feeder cattle during 1997 to 2009

Most beef cattle are transported at least once during their lives, and this potentially stressful practice may affect subsequent health and performance. Limited research is available quantifying the effects of transport on feedlot performance and health, and particularly the risk of bovine respiratory disease complex (BRD), which is the most common disease of weaned calves after arrival to the feedlot. The objective of this retrospective study was to determine potential associations between distance traveled (DTV) during transportation with health (cumulative BRD morbidity and mortality of all causes) and performance (ADG and HCW) parameters in cattle cohorts (n = 14,601) that arrived to 21 U.S. commercial feedlots from 1997 to 2009. Multivariable mixed-effects negative binomial and linear regression models were employed to determine associations between health and performance outcomes with DTV and other cohort-level demographic variables. Cattle were transported a median of 552 km from origin to feedlot with a mean (± SEM) of 698 ± 4.4 km. The mean (±SEM) cumulative BRD morbidity was 4.9% ± 0.01% (median = 1.1%; range: 0 to 100%) whereas the mean (±SEM) cumulative mortality due to all causes was 1.3% ± 0.01% (median = 0.8%; range: 0 to 28.7%). Distance traveled was significantly associated (P < 0.05) with BRD morbidity, overall mortality, HCW and ADG, and its effects were modified by demographic characteristics (i.e., cohort region of origin, mean arrival BW, gender, and the season of the year) of the cohort. Knowledge of the distance traveled during transportation could allow a more precise prediction of cattle feedlot health and performance.     

Prevalence of respiratory bacterial pathogens and associated management factors in dairy calves in Taiwan

This study aimed to investigate the prevalence at both farm-level and calf-level and to identify the risk factors of respiratory bacterial pathogens in dairy calves in Taiwan. The status of bovine respiratory disease (BRD) was evaluated by using the Wisconsin scoring system from a total of 400 pre-weaned calves from 32 different farms in Taiwan, then the nasopharyngeal swabs were collected. The prevalence of respiratory pathogens was 84.37% at farm-level and 45.50% at calf-level, and Pasteurella multocida (P. multocida) was the most prevalent pathogen. The presence of Mycoplasma bovis (M. bovis), P. multocida, Mannheimia haemolytica (M. haemolytica) and Histophilus somni (H. somni) were all higher in BRD positive calves than BRD negative calves, but only in H. somni was significant (P<0.001). Then nine farm management risk factors were analyzed by using multivariate logistic regression models to determine the risk factors of respiratory bacterial pathogens (farm and calf-level). In the result at farm-level, only unheated colostrum was significantly associated with pathogen positive farms (Odds Ratio (OR)=11.43). At calf-level, the predominant risk factor for each pathogen, M. bovis, P. multocida, M. haemolytica and H. somni, was late first colostrum feeding (OR=272.82), unheated colostrum (OR=3.41), waste milk feeding (OR=6.59) and high pneumonia treatment cost (OR=2.52), respectively. For effective preventive measures, farmer education on milk and colostrum feeding are urgently warranted.     

Comparison of a combination of oxfendazole and fenthion versus ivermectin in feedlot calves

A trial involving 6,169 feedlot calves was conducted under commercial feedlot conditions in western Canada to compare the relative efficacy of treatment with a combination of oxfendazole and fenthion (O/F) versus ivermectin (I) with respect to the outcome variables, final weight, gain, days on feed (DOF), dry matter intake (DMI), average daily gain (ADG), dry matter intake to gain ratio (DM:G), and morbidity, mortality, and carcass grade parameters.

There were no significant differences (p ≥ 0.05) between the treatment groups for final weight, gain, DOF, DMI, ADG and DM:G. In addition, there were no significant differences (p ≥ 0.05) in the carcass grading parameters between the treatment groups. The bovine respiratory disease (BRD) relapse rates, the overall mortality rates, and the cause specific mortality rates were not significantly different (p ≥ 0.05) between the treatment groups. The BRD treatment rate in the O/F group was significantly lower (p ≤ 0.05) than in the I group, but this difference was not economically important.

These data indicate that a combination of oxfendazole and fenthion is comparable to ivermectin with respect to performance, animal health, and carcass grade parameters.

     

A comparison of prophylactic efficacy of tilmicosin and a new formulation of oxytetracycline in feedlot calves

Two replicated-pen field studies were performed under commercial feedlot conditions in western Canada to compare the administration of long-acting oxytetracycline at 30 mg/kg body weight (BW) versus tilmicosin at 10 mg/kg BW to feedlot calves upon arrival at the feedlot. Ten thousand nine hundred and eighty-nine, recently weaned, auction market derived, crossbred beef steer and bull calves were randomly allocated upon arrival at the feedlot to one of 2 experimental groups as follows: oxytetracycline, which received intramuscular long-acting oxytetracycline (300 mg/mL formulation) at a rate of 30 mg/kg BW; or tilmicosin, which received subcutaneous tilmicosin (300 mg/mL formulation) at a rate of 10 mg/kg BW. There were 20 pens in each experimental group. In Study 1 and in the combined analysis, the initial undifferentiated fever (UF) treatment rate was significantly (P < 0.05) higher in the oxytetracycline group as compared with the tilmicosin group. There were no significant (P > or = 0.05) differences in first UF relapse, second UF relapse, third UF relapse, overall chronicity, overall rail, overall mortality, bovine respiratory disease (BRD) mortality, hemophilosis mortality, arthritis mortality, or miscellaneous mortality rates between the experimental groups in either study or in the combined analysis. In addition, there were no significant (P > or = 0.05) differences in initial weight, final weight, weight gain, days on feed, daily dry matter intake, average daily gain, or the dry matter intake to gain ratio between the experimental groups in either study or in the combined analyses. In the economic analysis, there was a net economic advantage of $5.22 CDN per animal in the oxytetracycline group, due to a lower prophylactic cost, even though the UF therapeutic cost was higher.